MedTrace Logo

Nutrition Impact on Immunotherapy of Cancer

NCT06500234 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-07-15

No results posted yet for this study

Summary

This study investigates nutritional status and outcomes of immuntherapy in cancer patients.

Conditions

  • Nutrition Disorders
  • Immunotherapy
  • Cancer
  • Survival, Prosthesis

Interventions

DRUG

Megestrol Acetate and olanzapine

megestrol acetate, 160 mg, oral everyday; olanzapine 2.5 mg, oral everyday

DRUG

Starch powder 50 mg

Starch powder 50 mg, oral, everyday

Sponsors & Collaborators

  • Qingdao Central Hospital

    lead OTHER

Principal Investigators

  • chunling zhang, MD · Qingdao Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-05-31
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06500234 on ClinicalTrials.gov